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ABSTRACT 
 
Diet-induced weight loss has been suggested to be harmful to bone health. We conducted a 
systematic review and meta-analysis (using a random-effects model) to quantify the effect of 
diet-induced weight loss on bone. We included 41 publications involving overweight or obese 
but otherwise healthy adults who followed a dietary weight-loss intervention. The primary 
outcomes examined were changes from baseline in total hip, lumbar spine, and total body 
bone mineral density (BMD), as assessed by dual-energy X-ray absorptiometry (DXA). 
Secondary outcomes were markers of bone turnover. Diet-induced weight loss was 
associated with significant decreases of 0.010 to 0.015 g/cm2 in total hip BMD for 
interventions of 6, 12, or 24 (but not 3) months' duration (95% confidence intervals [CIs], –
0.014 to –0.005, –0.021 to –0.008, and –0.024 to –0.000 g/cm2, at 6, 12, and 24 months, 
respectively). There was, however, no statistically significant effect of diet-induced weight loss 
on lumbar spine or whole-body BMD for interventions of 3 to 24 months' duration, except for a 
significant decrease in total body BMD (–0.011 g/cm2; 95% CI, –0.018 to –0.003 g/cm2) after 
6 months. Although no statistically significant changes occurred in serum concentrations of N-
terminal propeptide of type I procollagen (P1NP), interventions of 2 or 3 months in duration 
(but not of 6, 12, or 24 months' duration) induced significant increases in serum 
concentrations of osteocalcin (0.26 nmol/L; 95% CI, 0.13 to 0.39 nmol/L), C-terminal 
telopeptide of type I collagen (CTX) (4.72 nmol/L; 95% CI, 2.12 to 7.30 nmol/L) or N-terminal 
telopeptide of type I collagen (NTX) (3.70 nmol/L; 95% CI, 0.90 to 6.50 nmol/L bone collagen 
equivalents [BCEs]), indicating an early effect of diet-induced weight loss to promote bone 
breakdown. These data show that in overweight and obese individuals, a single diet-induced 
weight-loss intervention induces a small decrease in total hip BMD, but not lumbar spine 
BMD. This decrease is small in comparison to known metabolic benefits of losing excess 
weight. © 2015 American Society for Bone and Mineral Research 
 
Introduction 
 
Osteoporosis and its consequence of fragility fracture represent a significant burden on public 
health. Up to 38% of women and 8% of men aged 50 years and above are affected by 
osteoporosis.[1] From the age of 50 years, the residual lifetime risk of fracture is 47% for 
women and 22% for men.[2] In women, the lifetime risk of hip fracture is equivalent to or 
higher than the risk of invasive breast cancer.[3] More importantly, individuals with a hip 
fracture are at risk of further fracture and mortality.[4] Bone mineral density (BMD) is the most 
important predictor of fracture risk and mortality following a fracture. Each standard deviation 
decrease in BMD is associated with an approximately threefold increase in fracture risk.[5] 
Therefore, the diagnosis of osteoporosis is based on measurement of BMD. 
 In recent years, evidence has emerged that osteoporosis and obesity are linked. 
Obesity is a major public health risk and is now a worldwide epidemic, with a recent global 
analysis highlighting a 27% increase in overweight and obesity for adults between 1980 and 
2013.[6] Despite its association with various metabolic dysfunctions, obesity has been thought 
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to provide some protection against osteoporotic fractures, with high body mass indices (BMIs) 
said to be correlated with increased BMD.[7] However, this view that obesity has bone-
strengthening effects is now being questioned, with studies showing that the positive linear 
relationship between BMI and BMD is weaker at high BMIs,[8] and other studies suggesting 
that severe obesity (BMI ≥ 35 kg/m2) may be a risk factor for certain types of fractures.[9-11] 
For instance, a study involving over 60,000 women from 10 countries revealed an association 
between BMI ≥ 30 kg/m2 and increased risk of ankle and upper leg fractures (with reduced 
risk of wrist fractures),[10] and a similar correlation was also found in men, albeit only after 
correction for the increased BMD generally associated with obesity,[11] and not without 
controversy.[12] 
 Whether or not obesity per se has an effect on fracture risk, emerging evidence 
suggests that obesity treatment, namely bariatric surgery—which induces weight losses of up 
to 75% of excess body weight that are maintained for up to 10 to 14 years postsurgery[13]—
results in bone loss.[14, 15] However diet-induced weight loss, not bariatric surgery, with or 
without concomitant physical activity, is seen as the first treatment option for overweight and 
obesity.[16] Given that weight loss via lifestyle modification is also known to induce hormonal 
changes that would be expected to reduce both lean body mass[17] and bone mass,[18, 19] 
an increasing number of studies have investigated changes in bone mass in response to diet-
induced weight loss in overweight and obese individuals. 
 Of the studies that have investigated changes in bone mass in response to diet-
induced weight loss in overweight or obese adults, the results have been highly variable, with 
increases,[20-24] decreases,[25-40] and no change[22, 24, 26, 30, 33, 41-49] in bone mass 
being reported. Thus, attempting to draw sound conclusions from these mixed results is 
extremely difficult. However, definitive knowledge about any effects of diet-induced weight 
loss on bone is becoming increasingly important given the large numbers of people in our 
increasingly overweight and obese world population who are dieting for weight reduction. For 
instance, in 2011 to 2012, 17% (or 1.6 million) of the 9.2 million people in Australia who were 
overweight or obese reported being on a weight-reducing diet.[50] Although there have been 
a few previous reviews examining the effect of diet-induced weight loss on bone,[51-53] a 
formal quantitative assessment of its effect on bone health has not been performed. In the 
presence of conflicting findings from studies with limited sample sizes, a meta-analysis can 
be helpful in resolving the effect size. We thus conducted a systematic review and meta-
analysis to quantitatively determine the effects of diet-induced weight-loss interventions of any 
duration on bone mass as well as on circulating or urinary concentrations of biomarkers 
(“markers”) of bone formation or bone resorption (turnover) in overweight or obese men and 
women who were otherwise healthy. We included bone turnover markers in order to provide 
more sensitive assessment of the effects of diet-induced weight loss on bone in overweight 
and obesity because measurement of bone turnover markers can reveal treatment effects 
after only 2 to 3 months compared to a minimum of 6 months required before significant 
changes in BMD can be detected.[54, 55] 
 
Materials and Methods 
 
Inclusion and exclusion criteria for selecting studies for this review 
Study designs included in this analysis were randomized controlled trials, pilot studies, and 
cohort studies. Only original research studies were included; review articles, as well as 
abstracts and conference papers, were excluded. Included studies involved participants aged 
18 years or above who were overweight or obese (BMI ≥ 25 kg/m2) but otherwise healthy. 
Therefore, studies that specifically recruited participants with diseases such as type 2 
diabetes, osteoporosis, or cardiovascular disease were excluded. Included studies were 
required to implement a dietary weight-loss intervention involving the restriction of energy 
intake relative to participants' measured or estimated energy requirements and resulting in a 
reduction in average body mass of the group overall. No limit was placed on duration of the 
diet-induced weight-loss period. Studies were excluded if participants had undergone bariatric 
surgery or were taking medications designed to induce weight loss. Studies were also 
excluded if the intervention involved calcium supplementation or supervised exercise, or if 
exercise was the primary means of eliciting weight loss, because of potential confounding 
effects of calcium supplementation[35, 56] or physical activity on bone mass.[57] Because 
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physical activity is frequently recommended for weight management, to reduce publication 
bias we included interventions in which exercise was recommended as part of a healthier 
lifestyle, provided that the exercise was not supervised or was not the primary focus of the 
intervention. Any eligible nonsurgical, nonmedication, nonsupplementation, or nonexercise 
arms of any of the above such studies were included in this review. 
 Studies were included where one or more of the following outcomes were assessed: 
BMD of the total hip, lumbar spine (L1–L4 or L2–L4), or total body, as determined by dual-
energy X-ray absorptiometry (DXA), or serum concentrations of N-terminal propeptide of type 
I procollagen (P1NP) or osteocalcin (both bone formation markers), serum concentrations of 
C-terminal telopeptide of type I collagen (CTX), or serum or urinary concentrations of N-
terminal telopeptide of type I collagen (NTX) (bone resorption markers). We chose to 
investigate BMD of the hip and spine because these parameters are clinically relevant and 
are included in fracture risk algorithms, notably the World Health Organization's Fracture Risk 
Assessment tool (FRAX) and the Garvan Fracture Risk Calculator.[58] Indeed, the hip is the 
gold standard site both for the diagnosis of osteoporosis and the assessment of fracture 
risk.[59, 60] The spine, like the hip, is clinically significant because of its correlation with 
fracture risk.[60-62] Both of these sites, because of their high trabecular bone content and 
thus high bone surface area, are highly susceptible to factors that influence bone 
metabolism.[63] Although total body BMD is not used clinically for the diagnosis of 
osteoporosis or the estimation of fracture risk,[63] many studies have reported total body 
BMD, making it important to consider this parameter so as not to introduce bias in study 
selection. We chose to search for the abovementioned bone turnover markers because 
although there is currently no standardized set of bone markers for use in clinical practice and 
research, there have been several recent international recommendations to measure serum 
P1NP and CTX as the standardized reference markers of bone formation and resorption, 
respectively.[64-66] Although it has not been recommended to determine serum osteocalcin 
and serum or urinary NTX concentrations as markers of bone formation and resorption, 
respectively, they are also still commonly measured in conjunction with one or more of the 
recently recommended markers. Osteocalcin is of particular interest given a recent study 
showing a significant association between serum osteocalcin—but not P1NP or CTX—
concentrations with incident fracture risk in older men, even after adjusting for other risk 
factors.[67] To be included in this review, studies had to provide a within-subject comparison 
between baseline (ie, before commencement of the dietary weight-loss regime) and a time 
point immediately upon completion of the dietary regime. 
 
Search strategy 
MEDLINE, PreMEDLINE, EMBASE, CINAHL, and SPORTDiscus were searched from the 
inception date of each database to March 2014. Both medical subject headings (MeSH) and 
free-text search terms were employed. Limitations were set so that only studies published in 
English and involving human participants were found. Reference lists of relevant articles as 
well as review articles were searched to help ensure that all relevant studies were found. The 
Supporting Methods shows an example of the specific key words (or MeSH terms) that were 
used for the search of MEDLINE for population, intervention, and outcomes. 
 
Data collection, extraction, and analysis 
Two independent authors (JZ and MSHS) screened the titles and abstracts of studies 
identified in the above search strategy. The full texts of potentially relevant studies were 
retrieved, and the inclusion and exclusion criteria were applied. If discrepancies arose as to 
which studies to include, consensus was reached by consultation with a third author (RVS). 
The following data was extracted from each study, as summarized in Supporting Table 1: the 
number of participants in the study (sample size), the sex, menopausal status, age, and 
baseline BMI of participants (calculated from height and weight where BMI was not reported), 
duration and details of the dietary weight-loss intervention, time points at which outcomes 
were collected and used in this review, baseline weight, weight change from baseline at the 
end of the intervention, and results from one or more of the following parameters: BMD of the 
total hip, lumbar spine (L1–L4 or L2–L4) or of the total body, or circulating or urinary P1NP, 
osteocalcin, CTX, and NTX concentrations. 
 Some studies included more than one intervention that matched our inclusion 
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criteria[20, 22, 26, 28, 29, 32, 37, 42, 43, 68-70] In these instances, data from the different 
dietary weight-loss interventions were not pooled but were instead treated as independent 
interventions. For studies that reported both sexes independently,[20-22, 24, 29, 42, 44, 71-
75] data from both sexes were pooled before inclusion in our analysis. This is because the 
majority of studies did not report males or females separately, or did not include both sexes 
within their population. 
 Heights and weights were converted to meters (m) and kilograms (kg), respectively, 
when data were not already reported or provided in these formats. The durations of dietary 
weight loss interventions were expressed in months, with 1 month corresponding to 4 weeks 
for intervention durations that were reported in weeks. Dietary interventions that were not 2, 3, 
6, 12, or 24 months in duration were rounded to the nearest of these durations and included 
in that group for analysis, as shown in Supporting Table 1. Some interventions measured 
additional time points between baseline and the end of the dietary intervention. These shorter 
time points were also included as separate interventions, because they reflect the effect of 
shorter dietary interventions. Energy prescriptions for dietary weight-loss interventions were 
extracted in megajoules (MJ), with studies reporting energy prescriptions in calories being 
converted to MJ by multiplying by 0.00418. A very-low-energy diet (VLED) was defined as a 
diet providing less than 3.4 MJ per day,[76, 77] and a low-energy diet (LED) was defined as a 
diet providing greater or equal to 3.4 but less than 5.0 MJ per day.[76] A moderately energy-
restricted diet (MER) was defined as a diet providing greater or equal to 5.0 MJ per day.[78] 
BMD in all studies was reported as grams per square centimeter (g/cm2). Data for lumbar 
spine BMD measured between L1 and L4 were pooled with data measured between L2 and 
L4. In all studies, serum P1NP concentrations were reported in micrograms per liter (µg/L). 
Serum concentrations of osteocalcin were reported by studies in either nanomoles per liter 
(nmol/L) or µg/L. For this analysis we converted all data for osteocalcin to nmol/L using the 
molecular weight of osteocalcin as 5800.[79] The included studies reported serum 
concentrations of CTX in nmol/L or µg/L, depending on which manufacturer's assay was 
used. Because these methods are not comparable to each other, no conversion equation is 
available. Thus, data for serum CTX concentrations were separated according to the units 
reported by the original studies (nmol/L or µg/L). NTX concentrations were also analyzed in 
two distinct data sets because measurements had been made either in serum or urine, both 
of which also have their own units of measurement and noncomparable concentrations; 
nmol/L bone collagen equivalents (BCE) for serum, and nmol/L BCE/nmol/L creatine for urine. 
Corresponding authors were contacted if any required data was not available from the 
publication or was published in a format different from that required for this meta-analysis.[20, 
22-25, 28, 35-37, 39, 42-47, 69-71, 73, 74] For authors from whom we did not receive a 
response,[24, 49, 75] data for their publications were analyzed qualitatively rather than 
quantitatively. 
 
Data synthesis and analysis 
Our primary outcomes were the change in BMD at the total hip, lumbar spine, and total body, 
and secondary outcomes were the change in serum P1NP, serum osteocalcin, serum CTX, 
and serum or urinary NTX concentrations from baseline (ie, before commencement of the 
dietary weight-loss intervention) to a time point immediately after the dietary intervention. 
Weight loss between baseline and the end of the dietary intervention was also analyzed. 
 The synthesis of data was performed with a random-effects meta-analysis model. 
Briefly, we calculated effect size and its variance for each study. The effect size, di, was the 
weighted mean difference between measures taken before and after the dietary weight loss 
intervention, with the weight being inverse to the variance for each study. It is assumed that 
each di is normally distributed with a “true” but unknown mean of ti and a within-study 
variance of . The collection of i across studies is further assumed to follow a normal 
distribution with an unknown mean of δ0 and a between-study variance of s2. The random-
effects model recognizes the possibility of heterogeneity of between-study variation (ie, that 
n2 could be different from 0) but with a fixed value. 
 The heterogeneity of effects across studies was assessed by computing the 
coefficient of inconsistency (I2), which is the proportion of total variation among studies that is 
due to between-study heterogeneity. An I2 exceeding 50% is regarded as evidence of 
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substantial heterogeneity, indicating that secondary analyses are required to determine 
whether differences in primary outcomes may be due to differences in various parameters 
among participants. We decided a priori that if substantial heterogeneity was observed 
between studies, we would conduct subgroup analyses for the type of dietary weight loss 
intervention under study (VLED or LED versus MER) and menopausal status (premenopausal 
versus postmenopausal). In order to avoid duplication of data in these subgroup analyses, 
changes from baseline to the end of the dietary intervention were included in the analysis, but 
changes from baseline to any additional time points measured before the end of the 
intervention were not. Because of the limited number of studies available, duration of dietary 
intervention was not taken into account for such subgroup analyses, with all studies being 
pooled into their corresponding type of dietary intervention or menopausal status regardless 
of diet duration. To further explore any heterogeneity identified, we also conducted meta-
regression analysis of change in the parameter of interest versus baseline body weight and 
baseline BMD. It was not possible to assess whether other differences amongst participants 
(ie, sex and age) contributed to differences in primary outcomes, because separate data from 
men or women or from people of clearly defined age groups were not available for most 
studies. 
 Publication bias was investigated visually with a funnel plot and confirmed with an 
Egger's test. Due to the nature of this meta-analysis, where data were compared before and 
after an intervention, the usual quality filters that apply to randomized controlled trials or 
observational studies could not be applied. All statistical analyses were conducted using 
STATA software version 13.0 (StataCorp, College Station, TX, USA). 
 
Results 
 
Characteristics of clinical trials 
As seen in Supporting Fig. 1, 3145 publications were retrieved from the five databases 
searched, equating to 2765 unique publications. Following screening of titles and abstracts, 
the full texts of 71 publications were then retrieved and analyzed against the inclusion and 
exclusion criteria, resulting in the exclusion of 30 publications for the reasons shown in 
Supporting Fig. 1. There were no further publications identified from screening references lists 
of these 71 full-text publications. As a result, 41 publications were included in this report, with 
38 of them being included in the meta-analysis and the other three[24, 49, 75] being analyzed 
qualitatively; 31 reporting on BMD outcomes (29 being included in the meta-analysis) and 23 
reporting on bone turnover markers (21 of which were included in the meta-analysis) 
(Supporting Fig. 1). 
 The publications included in this report are listed alphabetically in Supporting Table 1. 
Sample sizes varied from n = 9 to 164, averaging 46 participants per study. The studies 
included either males and females or females only, with females being divided in some cases 
into premenopausal and postmenopausal status (Supporting Table 1). The lowest reported 
mean age of participants in any study was 33.7 years, and the greatest mean age was 70 
years. BMI values ranged from a minimum mean average of 25.6 kg/m2 (overweight) to a 
maximum mean average of 39.3 kg/m2 (obese). Mean body weight for participants in the 
included studies ranged from 67.2 to 111.6 kg. 
 and high protein diets, so the total number of interventions reported in the 38 
publications used for this meta-analysis was 53. Dietary weight-loss interventions differed 
among studies with respect to both the duration and details of intervention (Supporting Table 
1). A number of publications measured outcomes for each intervention at more than one time 
point (eg, after 3 and 6 months on a 6-month intervention), and the total number of 
observations for these 38 publications and 53 interventions was 64. 
 
Meta-analysis 
Total hip BMD 
In summary, this meta-analysis shows significant reductions by 0.010 to 0.015 g/cm2 in total 
hip BMD after dietary weight loss interventions of 6 to 24 months in duration. There was 
significant heterogeneity of effects among interventions, partly due to differences in energy 
restriction (there was a significant reduction in total hip BMD with MER but not with severe 
energy restriction via VLED or LED). Heterogeneity could not be attributed to differences 
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among participants in menopausal status or baseline body weight or baseline total hip BMD. 
Total hip BMD data were available from 13 interventions with 23 observations and 889 
participants. The average weight losses ranged from 7 to 11 kg (Fig. 1A), depending on the 
duration. Mean ± SE of total hip BMD at baseline was 1.01 ± 0.02 g/cm2. Total hip BMD 
decreased at all time points investigated (3, 6, 12, and 24 months), significantly so at 6 
months (–0.010 g/cm2; 95% CI, –0.014 to –0.005 g/cm2; p = 0.001), 12 months (–0.015 g/cm2; 
95% CI, –0.021 to –0.008 g/cm2; p = 0.001), and 24 months (–0.012 g/cm2; 95% CI, –0.024 to 
0.000 g/cm2; p = 0.047), as shown in Fig. 1A. Significant heterogeneity was found among 
interventions lasting 12 months and 24 months, but not among those of 3-month or 6-month 
duration, as seen from the I2 statistics in Fig. 1A. 
  
Figure 1. 
Forest plot of change in (A) total hip BMD and (B) serum osteocalcin from baseline until the end of dietary weight loss 
interventions of varying durations. MWC during the dietary interventions are recorded next to the corresponding 
duration, ±SDs. The letter in parentheses to the right of each study is used to distinguish different dietary 
interventions from the same publication, with details of all corresponding dietary interventions listed in Supporting 
Table 1. Plotted values (and the numbers at right) represent the absolute changes in (A) total hip BMD (in g/cm2) and 
(B) serum osteocalcin concentrations (in nmol/L), with 95% CIs illustrated by the error bars (or the numbers in 
parentheses at right). Mean ± SE of total hip BMD and serum osteocalcin concentrations at baseline were 
1.01 ± 0.02 g/cm2 and 1.6 ± 0.5 nmol/L, respectively. I2 indicates the percentage of heterogeneity for the dietary 
interventions of each duration. BMD = bone mineral density; MWC = mean weight changes; CI = confidence interval. 
 
 Because of this significant heterogeneity in the data at 12 and 24 months, subgroup 
analyses were conducted to explore for potential contributing factors. All interventions were 
divided according to the degree of energy restriction (VLED or LED versus MER as outlined in 
the Materials and Methods), regardless of the duration of the dietary intervention. Weight loss 
was greater with VLED or LED (–11.1 kg; 95% CI, –14.4 to –7.8 kg; p = 0.001 versus 
baseline), than with MER (–9.6 kg; 95% CI, –10.8 to –8.6 kg; p = 0.001 versus baseline). 
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Although total hip BMD decreased with both types of dietary intervention, the decrease was 
significant only with MER (–0.013 g/cm2; 95% CI, –0.018 to –0.008 g/cm2; p = 0.001). 
Menopausal status had no significant effect on the effect of weight loss on total hip BMD (data 
not shown). To further explore possible reasons for the heterogeneity in outcomes, we 
conducted a meta-regression analysis of change in total hip BMD versus baseline body 
weight and baseline BMD using the 13 studies that investigated total hip BMD after 6 or 12 
months. However, this analysis did not show any linear relationship between change in total 
hip BMD and baseline body weight (p = 0.757) or baseline BMD (p = 0.467), suggesting that 
differences in these baseline parameters could not account for variability in the results. This 
finding also suggests that the reduction in total hip BMD was unlikely because of the 
statistical phenomenon of regression toward the mean, whereby variables that are higher or 
lower than the mean upon first measurement will tend to be closer to the mean the next time 
they are measured, even without intervention. The Egger's test and funnel plot revealed no 
significant publication bias for the change in weight (p = 0.967) or total hip BMD (p = 0.492). 
 
Lumbar spine BMD 
To summarize, this meta-analysis shows no significant overall effect of diet-induced weight 
loss on lumbar spine BMD. However, there was significant heterogeneity of effects among 
interventions. This heterogeneity was related to differences in energy restriction and 
menopausal status, with a significant decrease in lumbar spine BMD in interventions involving 
VLED or LED but not MER, and in interventions involving premenopausal but not 
postmenopausal women. 
 BMD at the lumbar spine showed variable responses to diet-induced weight loss, with 
increases, decreases, and no change in this parameter being found from the baseline mean ± 
SE values of 1.16 ± 0.03 g/cm2 in a total of 20 interventions and 29 observations in 1097 
participants, with no overall significant differences being identified by this meta-analysis at 
any time point (Supporting Fig. 2). Significant heterogeneity between studies was present at 3 
and 12 but not at 6 or 24 months. VLED or LED caused a significant decrease in BMD of the 
lumbar spine across all time points (–0.031 g/cm2; 95% CI, –0.062 to 0.000 g/cm2; p = 0.05), 
with no significant change in this parameter in response to MER (0.002 g/cm2; 95% CI, –
0.003 to 0.007 g/cm2; p = 0.497). This result was opposite to that found for the total hip as 
described in the previous section, where BMD was significantly decreased only in response to 
MER and not in response to VLED or LED. When menopausal status was investigated, BMD 
of the lumbar spine decreased significantly only in premenopausal women (–0.023 g/cm2; 
95% CI, –0.005 to 0.000 g/cm2; p = 0.05) and not in postmenopausal women (0.002 g/cm2; 
95% CI, –0.011 to 0.016 g/cm2; p = 0.726). Therefore, although no significant effect of diet-
induced weight loss on lumbar spine BMD was found when the data were pooled according to 
the duration of dietary interventions, significant effects were found when the studies were 
analyzed according to the diet type and menopausal status of the participants. No evidence of 
publication bias was found. 
 
Total body BMD 
In summary, apart from a significant decrease of 0.011 g/cm2 in total body BMD after dietary 
weight-loss interventions of 6 months in duration, this meta-analysis showed no overall effect 
of diet-induced weight loss on total body BMD. There was significant heterogeneity of effects 
among interventions, related to differences in energy restriction (there was a significant 
increase in total body BMD with VLED or LED but not MER), and differences in menopausal 
status (there was a significant decrease in total body BMD in postmenopausal but not 
premenopausal women). 
 Supporting Fig. 3 depicts the forest plot for the change in BMD of the total body in 
response to diet-induced weight loss in 32 interventions and 37 observations including a total 
of 883 participants (mean ± SE at baseline of 1.17 ± 0.02 g/cm2). For dietary interventions of 
durations of 3 and 12 months, no significant changes from baseline in total body BMD were 
found (p = 0.119, and p = 0.619, respectively). For dietary interventions that had a duration of 6 
months, however, a significant decrease from baseline in total body BMD was observed (–
0.011 g/cm2; 95% CI, –0.018 to –0.003 g/cm2; p = 0.004). Significant heterogeneity was 
observed for interventions of 3 and 12 months' duration. VLED or LED resulted in a significant 
overall increase in total body BMD (p = 0.001) compared to a nonsignificant increase in this 
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parameter in response to MER (p = 0.59). Although both premenopausal and postmenopausal 
women lost a similar amount of body weight, and although BMD of the total body decreased 
in both premenopausal and postmenopausal women, the effect of diet on total body BMD was 
significant only in the postmenopausal women (p = 0.006). This finding is different to that 
identified in the results for total hip and lumbar spine BMD, where no change in total hip BMD 
was found in either premenopausal or postmenopausal women, and a significant decrease in 
lumbar spine BMD was only detected in the premenopausal cohort. No publication bias was 
detected. 
 
P1NP 
There were eight interventions and 10 observations that investigated the effect of diet-induced 
weight loss on serum concentrations of the bone formation marker, P1NP, in a total of 176 
participants with a mean ± SE at baseline of 40.8 ± 3.3 µg/L. Serum P1NP concentrations 
showed no significant change in response to diet at any time point (Supporting Fig. 4). No 
heterogeneity was observed for serum P1NP. 
 
Serum osteocalcin 
To summarize, this meta-analysis showed that 3-month diet-induced weight-loss interventions 
were associated with a significant increase in serum osteocalcin concentrations. However, the 
effect was not observed when measured after interventions of 6, 12, or 24 months in duration. 
There was significant heterogeneity among studies, due at least in part to differences in 
energy restriction but not menopausal status, with a significant increase in osteocalcin being 
observed after MER but not after VLED or LED. 
 There were 25 interventions and 32 observations that investigated the effect of diet-
induced weight loss on serum concentrations of the bone formation marker, osteocalcin, in a 
total of 827 participants with a mean ± SE at baseline 1.6 ± 0.5 nmol/L. Overall, serum 
osteocalcin concentrations tended to increase with diet-induced weight loss (Fig. 1B), with a 
significant increase occurring in response to dietary interventions of 3 months' duration 
(0.26 nmol/L; 95% CI, 0.13 to 0.39 nmol/L; p = 0.001). Heterogeneity was present only at 12 
months. Weight reduction was greater with VLED or LED (–13.7 kg; 95% CI, –23.3 to –4.2 kg; 
p = 0.005 versus baseline) than with MER (–6.8 kg; 95% CI, –23.3 to –6.1 kg; p = 0.001 versus 
baseline). However, a significant increase in osteocalcin was only found in response to the 
MER (0.10 nmol/L; 95% CI, 0.01 to 0.19 nmol/L; p = 0.025 versus baseline) and not in 
response to the VLED or LED (0.23 nmol/L; 95% CI, –0.68 to 1.13 nmol/L; p = 0.624 versus 
baseline). This finding is consistent with that for BMD of the total hip, where a significant 
decrease occurred in response to MER but not VLED or LED, yet opposite to that for the 
lumbar spine, which favored MER over VLED for effects on BMD. No significant changes from 
baseline to the end of the dietary intervention were present with the limited number of 
interventions having a specifically premenopausal or postmenopausal status (premenopausal: 
0.17 nmol/L; 95% CI, –0.14 to 0.48 nmol/L; p = 0.290; postmenopausal: 0.06 nmol/L; 95% CI, –
0.06 to –0.18 nmol/L; p = 0.320). There was no publication bias. 
 
Serum CTX 
Serum CTX was investigated and reported in nmol/L units in five interventions and five 
observations with a total of 103 participants, all with a 3-month duration and a mean ± SE at 
baseline of 12.5 ± 1.5 nmol/L (Supporting Fig. 5). A significant increase in this parameter was 
observed (4.72 nmol/L; 95% CI, 2.12 to 7.31 nmol/L; p = 0.001 versus baseline). There was no 
significant heterogeneity detected, so no secondary analyses were performed for this 
parameter. Serum CTX was investigated and reported in µg/L units in eight interventions and 
10 observations involving 486 participants overall and a mean ± SE at baseline of 
0.51 ± 0.09 µg/L (Supporting Fig. 6). There was a nonsignificant trend for an increase in this 
parameter for interventions of 2 months in duration, and a significant increase for 
interventions of 3 months in duration (0.21 µg/L; 95% CI, 0.13 to 0.29 µg/L; p = 0.001 versus 
baseline), albeit that finding stems from the results of a single intervention.[71] However, 
dietary interventions that were 6, 12, or 24 months in duration produced no overall significant 
change in serum CTX concentrations compared to baseline and reported in µg/L (Supporting 
Fig. 6). Significant heterogeneity for serum CTX in µg/L occurred at 6 and 12 months, but 
subgroup analysis was not performed for this parameter because of the limited number of 
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studies available. Indeed, only one study that investigated serum CTX in µg/L used an LED, 
and only one study investigated a distinctly premenopausal population. 
 
Serum and urinary NTX 
There were 14 interventions and 17 observations that investigated serum or urinary NTX 
concentrations in a total of 306 participants. For both serum (Supporting Fig. 7) and urinary 
(Supporting Fig. 8) concentrations of the bone resorption marker NTX, there was an overall 
trend for an increase from baseline mean ± SE values of 15.5 ± 1.2 nmol/L BCE and 37.4 ± 4.1 
nmol/L BCE / nmol/L creatine, respectively, in response to diet-induced weight loss. A 
significant increase only occurred for serum NTX in response to a 2-month diet-induced 
weight loss intervention, albeit this time point only included one study[80] (3.70 nmol/L BCE; 
95% CI, 0.90 to 6.50 nmol/L BCE; p = 0.010 versus baseline). No heterogeneity was observed 
for serum or urinary NTX. 
 Qualitative analysis of studies that could not be included in the meta-analysis 
For the three publications[49, 75, 81] that were not able to be included quantitatively in this 
meta-analysis, the findings are broadly consistent with results from the meta-analysis. 
Svendsen and colleagues[49] placed 50 overweight postmenopausal women on a diet 
involving MER for 3 months, thereby inducing significant weight loss (–9.5 ± 0.4 kg; p = 0001 
versus baseline). Lumbar spine and total body BMD were investigated, with nonsignificant 
decreases being observed in both parameters when measured at 3 months. The second 
study, by Thorpe and colleagues,[24] investigated the effect of a 12-month high-protein or 
high-carbohydrate weight-reducing diet on total hip, lumbar spine, and total body BMD in 130 
male and female participants. In the cohort on the high-protein weight-reducing diet, BMD 
was significantly increased at all sites investigated, whereas the cohort on the high-
carbohydrate weight-reducing diet showed a nonsignificant trend toward decreased BMD at 
all three sites (total hip, lumbar spine, and total body). Hyldstrup and colleagues[75] 
investigated serum osteocalcin concentrations in 44 obese men and women undergoing a 
VLED for 2 months, with 24 participants continuing to 8 months on the diet. A significant 
increase in serum osteocalcin concentrations occurred at 2 months, and this increase over 
baseline values was still present when measured at 8 months, with no significant difference 
between values recorded at 2 and 8 months. 
 
Discussion 
 
Whether or not diet-induced weight loss exerts an adverse effect on bone health has been a 
controversial issue. In this study, by using a meta-analysis approach, we have shown that 
dietary weight-loss interventions were associated with a small but statistically significant 
reduction in total hip BMD, and the effect could be seen from the sixth month of intervention 
onward. We did not, however, find any significant effect of diet-induced weight loss on BMD of 
the clinically relevant site of lumbar spine. Importantly, we found that the decrease in total hip 
BMD occurred subsequent to statistically significant increases in serum concentrations of 
osteocalcin, CTX, and NTX, suggesting that weight-loss diets increase bone turnover, albeit 
perhaps only transiently, with consequences for total hip but not spine BMD. 
Although the effect was small, several lines of evidence support a real effect of diet-induced 
weight loss to reduce total hip BMD. First, of the less than 25% of studies in this review that 
included a control group,[22, 25, 36, 40, 45-47, 73, 74, 80, 82] there were no significant 
changes in BMD[22, 25, 46, 47] or bone turnover markers[22, 36, 45-47, 73, 80] in the control 
group over the time frames investigated in this review, with the exception of four studies[36, 
40, 45, 74] investigating postmenopausal women or people older than 65 years. Second, the 
Dubbo Osteoporosis Epidemiology Study showed that women with a baseline body weight 
over 70 kg did not show any reduction in BMD over an average interval of 2.7 years, in 
contrast to the significant bone losses seen in women weighing up to 70 kg.[83] Therefore, 
because the mean baseline body weight of participants in all but one[34] of the studies 
included in our meta-analysis was over 70 kg, it is likely that loss of total hip BMD in this 
population was a real effect of diet-induced weight loss. Third, the significant increases in 
circulating concentrations of bone turnover markers suggest a bone catabolic state. It is 
important to consider bone turnover markers in this field of research, because the accuracy 
and precision of DXA is known to decrease with increasing BMI[84] and when participants 
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undergo changes in body weight,(85–88) and because BMD measured at time points earlier 
than 6 months are not considered to be clinically significant, given that a complete cycle of 
bone remodeling takes 4 to 6 months.[53] Thus, diet-induced weight loss induces small but 
statistically significant losses in total hip BMD that would likely not otherwise be seen in 
overweight or obese individuals. 
 It is not clear whether the significant reduction in total hip BMD represents a 
maladaptive change, or whether it simply represents normalization of BMD relative to reduced 
body mass after diet-induced weight loss, akin to the finding that a certain loss of percent fat-
free mass is to be expected in response to reduced BMI.[89] The statistically significant 
decreases in BMD observed in this meta-analysis (–0.010 to –0.015 g/cm2) represent an 
approximately 1% to 1.5% change from baseline values, which is similar to the average yearly 
BMD loss for elderly women.[83, 90] In an untreated population, each standard deviation 
decrease in femoral neck BMD (which is 0.12 g/cm2) was associated with an approximately 
3.5-fold increase in the risk of hip fracture.[91] Thus, it can be estimated that a 0.010 to 0.015 
g/cm2 decrease in BMD is equivalent to an approximately 10% to 15% increase in fracture 
risk. It would therefore appear unlikely that a single dietary weight-loss intervention of 6 to 24 
months' duration would have any prevailing negative impact on bone, and should be safe for 
most overweight or obese people. However, given that long-term obesity management 
typically involves multiple periods of diet-induced weight loss, repeated at intervals over many 
years, potential cumulative adverse effects on bone should be considered, especially in those 
at risk of accelerated bone loss, such as older or inactive women.[83] In keeping with this 
possibility, a prospective cohort study in 6785 lean and overweight or obese women aged 65 
years and over found that losing 5% or more of initial body weight over an average 5.7-year 
period, whether intentionally or unintentionally and irrespective of current weight, significantly 
increased the rate of hip BMD loss and doubled the risk of hip fracture.[90] Moreover, a 
population-based study of 20,745 men and women in Tromsø, Norway, showed that women 
who recalled dieting and losing 11 kg or more, or who recalled 11 or more dieting episodes, 
had an adjusted hazard ratio for nonvertebral osteoporotic fractures of 1.48 or 1.73 in a mean 
follow-up period of approximately 12 years, compared to women with no recollection of 
dieting.[92] Thus, although a single diet-induced weight-loss intervention may not increase 
fracture risk by a clinically relevant degree, caution may be warranted for repeated episodes 
of diet-induced weight loss. 
 Unlike the total hip, no significant effect of diet-induced weight loss was observed in 
the lumbar spine. This may be due in part to the greater measurement error that occurs in the 
lumbar spine in comparison to the hip.[53] DXA scans of the spine, in particular the lumbar 
region (L1–L5), often pick up calcification from other sources besides healthy vertebrae, and 
this increases apparent BMD readings.[93, 94] Such calcification can originate from 
atherosclerotic lesions within the aorta, or from osteophytes (protrusions of bone tissue that 
form in response to joint damage from conditions such as in arthritis), masking underlying 
changes in bone mass due to age, disease, or other factors.[93, 95] Therefore the validity of 
lumbar spine BMD results can be questionable, highlighting the greater reliance on total hip 
BMD measures for the estimation of fracture risk.[58, 60, 64, 82, 96] 
 The majority of studies identified in this systematic review and meta-analysis 
investigated total body BMD, which was significantly reduced by 6-month (but not by 3-month 
or 12-month) weight-loss interventions. However, measures of total body BMD are not 
clinically relevant because they do not identify specific areas that are affected by loss of bone 
mass. In osteoporosis, bones with a high proportion of trabecular as opposed to cortical bone 
tissue, such as the hip and spine, have an increased likelihood of degradation.[63] When 
subregions of whole-body DXA scans, such as the pelvis, are used to measure BMD rather 
than the total hip or proximal femur, underdiagnosis of osteoporosis occurs.[97, 98] 
Therefore, local DXA scans of specific bone regions should be performed rather than, or in 
conjunction with, total body scans when investigating BMD. 
 We initially hypothesized that any diet-induced reductions in BMD and increases in 
bone turnover would be more clearly apparent after interventions involving VLED or LED 
versus those involving MER, due to the greater severity of energy restriction used. This is 
because energy restriction induces hormonal changes that might be expected to decrease 
bone mass,[18, 53] and the effects may be more pronounced with severe than with moderate 
energy restriction.[99] An additional rationale for this hypothesis is that severe energy 
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restriction induces greater weight loss than MER,[100] which would lead to greater 
mechanical unloading of bone, with subsequently greater bone loss. Mechanistic support for 
this comes from the finding that weight loss–induced reductions in BMD and bone quality in 
older adults are correlated with increases in circulating concentrations of sclerostin, an 
osteoblastic inhibitor released from osteocytes in response to mechanical unloading.[101] 
Furthermore, we hypothesized that postmenopausal women would exhibit more detrimental 
changes in bone mass and turnover in response to diet-induced weight loss than 
premenopausal women, because they are already predisposed to detrimental changes in 
bone. However, our subgroup analyses did not provide any clear evidence to support or refute 
these hypotheses. The conflicting results identified emphasize the need for further 
investigation into the effects of diet types on bone, as well as interaction of the effect with 
menopausal status. 
 The present findings should be considered within the context of strengths and 
weaknesses. To the best of our knowledge, this is the first and the most comprehensive 
review of the effect of diet-induced weight loss on bone loss, as assessed in clinical trials. The 
measurement of BMD in individual studies was done with DXA technology, which is 
considered the gold standard for the assessment of bone mass. However, it was not possible 
to determine the effects of sex or age on the changes in bone mass or turnover with weight 
loss. This is because the majority of studies investigated female populations only. In studies 
where both males and females were included,[20-22, 24, 29, 42, 44, 71-75] the two sexes 
were not always reported independently.[22, 29, 42, 44, 74] Additionally, although age was 
reported in all studies, large age ranges prevented us from being able to assign the outcomes 
to a younger or older population for comparison. Another limitation of this meta-analysis was 
the widely varying types of dietary interventions. Although we were able to categorize 
interventions according to the levels of prescribed energy intake, this did not take into account 
differences in macronutrient composition of the diets. A further limitation of this meta-analysis 
was that only 25% of the included studies involved comparison with a control 
group,(22,25,36,40,45–47,73,74,80,82) as mentioned in the second paragraph of this 
Discussion. 
 This meta-analysis has not only highlighted significant changes that occur in bone 
physiology in response to diet-induced weight loss, it has also crystallized gaps in the 
literature where further research is required. First, mathematical modeling and bone structural 
analyses would be required to determine whether the presently-observed changes in bone in 
response to diet-induced weight loss represent benign normalization of bone mass to the 
reduced body weight or the onset of potentially pathological processes. Second, only a 
minority of studies reviewed herein investigated BMD at time points after the end of the 
dietary intervention. This prevented us from being able to assess whether the changes that 
were observed immediately after finishing the weight-loss diet persisted or resolved once the 
dietary intervention had ceased. Of the studies that did include a follow-up time point,[21, 23, 
25, 27, 28, 30, 39, 74] decreases in BMD of the total hip,[23, 30, 74] lumbar spine,[25, 28, 30] 
and total body[21, 27, 28, 30, 39] were still present when measured at 3 to 21 months after 
completion of the dietary weight-loss intervention, raising potential concerns about the long-
term impact of repeated weight-loss diets on bone. Hence, it would be important that future 
studies investigate the longitudinal effects of dietary weight-loss interventions on bone, as in 
two current trials by our research team.[102, 103] An additional outstanding question is the 
change in fracture risk that may occur as a result of BMD loss subsequent to diet-induced 
weight loss in overweight or obese people. None of the studies included in this analysis 
estimated change in fracture risk as a result of the diet, with only one study[23] reporting Z 
and T scores (which are needed to calculate fracture risk in some algorithms) in conjunction 
with BMD in g/cm2. Therefore, future research should aim to incorporate BMD values of the 
lumbar spine and/or hip, Z and T scores, as well as an assessment of fracture risk when 
investigating the influence of diet-induced weight loss on bone. Further research may also be 
needed to address the kinds of interventions that could aid in preventing bone loss in 
response to diet-induced weight loss. Currently, there is some, but little evidence from 
randomized controlled trials indicating that calcium supplementation attenuates the bone loss 
that occurs with weight loss, and that a higher dietary protein intake and exercise[101] also 
have similar effects, as highlighted previously.[53, 104, 105] Because this meta-analysis 
included diet-induced weight-loss interventions with higher dietary protein intakes (but not 
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those involving calcium supplementation), as well as those that recommended but did not 
supervise physical activity, the effect of diet-induced weight loss on bone may be even more 
pronounced than that suggested in the current analysis for individuals on lower-protein 
weight-loss diets and/or not engaging in regular physical activity. Additionally, although our 
subgroup analyses suggested that VLEDs or LEDs do not seem to have any worse effect on 
bone than do MERs, there were limited studies available testing VLEDs or LEDs, and only 
three[22, 28, 70] in direct comparison to less severe energy restriction (ie, MER). Thus more 
work is needed in this domain, given the increasing use of severe energy restriction for the 
management of overweight and obesity. 
 Obesity is a major health concern that requires treatment to prevent or attenuate 
associated health issues and diseases. This meta-analysis shows that BMD of the total hip 
decreases with diet-induced weight loss in overweight or obese people, in conjunction with an 
early rise in bone turnover, but the change induced by a single intervention is small in 
comparison to the benefits for metabolic health. Thus, clinicians should continue to 
recommend weight loss for the treatment of overweight and obesity, with support for weight 
maintenance after weight loss. 
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